Estimation of Serum Copper Level in Benign & Malignant Prostate Disease & Correlation with Acid Phosphatase

Abstract

Objective: To estimate and compare the serum copper level in patients with benign prostatic hypertrophy and prostate carcinoma and their correlation with serum acid phosphatase. Methods: This case control study was conducted at department of Biochemistry, Isra University Hyderabad from April 2016 to November 2016. A total of 100 individuals were divided into three groups. Group A consisted of 50 healthy individuals as Controls whereas; Group B and group C included 25 patients each with Benign Prostatic Hyperplasia (BPH) and Prostatic cancer respectively. Individuals taking copper supplements ,r any other trace elements and heavy metal supplements for the past three months were excluded from the study. Blood samples were collected from all cases and biochemical analysis for serum copper and prostatic acid phosphatase was performed in the Isra University Diagnostic and Research Laboratory, Hyderabad. All the results obtained were statistically analyzed. Results: Prostatic acid phosphatase in Group A was 2.28± 0.99, Group B 16.03± 5.89 and Group C 46.43 6.22 UIL respectively. P- value of 0.0001 was noted among all 3 groups. Serum copper levels in Group A was 106.88± 19.28, Group B 104.29± 17.40 and Group C 92.88± 11.28fig/L. respectively. P value between groups A vs B, A vs C and B vs C were noted as 0.052, 0.001 and 0.022 respectively. Serum copper was reduced in group B compared to A but P value showed no significant difference (p-0.05 21. However, A vs C and B vs C showed statistically significant differences. Conclusion: The present study reports the raised prostatic acid phosphatase, and decreased serum copper levels in carcinoma of prostate gland indicating their diagnostic and prognostic significance.